Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (116)	8/17/1998 11:22:00 AM
From: Pseudo Biologist	Respond to of 666

V1, you are, of course, correct on focusing on Bexxar. That's why I am not too embarrassed about my ignorance of their TAP program. PB

To: Vector1 who wrote (116)	4/5/1999 2:48:00 PM
From: LLCF	Read Replies (3) \| Respond to of 666

I've heard some negative comments on CLTR, especially their ability to obtain FDA approval this year (Bexxar) due to reliance on 3 additional clinical trails to support its application. The comments include claims that the company is having a hard time with enrollment of these studies and manufacturing issues to be resolved due to the inability to stockpile radiolabled antibodies. Don't mean to just toss this junk out here, just wonder if anyone has a comment on these or have heard of them before? DAK